Michael Mason Biography and Net Worth

Mike joined Karyopharm in February 2019 and is responsible for leading and directing the financial activities of the Company. He has over 18 years of diversified financial experience in executing financial strategies and leading growth initiatives for life sciences companies. He has deep expertise in global financial operations and controls, financing transactions, business planning and supporting pharmaceutical product launches.

Prior to joining Karyopharm, Mike spent over 13 years at Alnylam Pharmaceuticals, Inc. in a progression of finance roles. Most recently, he served as Vice President of Finance and Treasurer at Alnylam. Earlier in his career, Mike served as the Corporate Controller at Praecis Pharmaceuticals and previously worked in the audit practice at KPMG LLP, a national audit, tax and advisory services firm.

Mike received a Bachelor of Business Administration from Stetson University and an MBA from Babson College. He is also a Certified Public Accountant.

What is Michael Mason's net worth?: The estimated net worth of Michael Mason is at least $99,259.60 as of June 4th, 2024. Mr. Mason owns 26,540 shares of Karyopharm Therapeutics stock worth more than $99,260 as of April 1st. This net worth approximation does not reflect any other assets that Mr. Mason may own. Learn More about Michael Mason's net worth.
How do I contact Michael Mason?: The corporate mailing address for Mr. Mason and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at ikarp@karyopharm.com. Learn More on Michael Mason's contact information.
Has Michael Mason been buying or selling shares of Karyopharm Therapeutics?: Michael Mason has not been actively trading shares of Karyopharm Therapeutics during the past quarter. Most recently, Michael Mason sold 43 shares of the business's stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $14.85, for a transaction totalling $638.55. Following the completion of the sale, the chief financial officer now directly owns 26,540 shares of the company's stock, valued at $394,119. Learn More on Michael Mason's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Michael Kauffman (Director), Michael Mason (CFO), Stephen Mitchener (SVP), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, insiders at the sold shares 13 times. They sold a total of 86,435 shares worth more than $1,257,559.20. The most recent insider tranaction occured on October, 4th when CEO Richard A Paulson sold 240 shares worth more than $3,168.00. Insiders at Karyopharm Therapeutics own 2.8% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 10/4/2024.

Michael Mason Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/4/2024	Sell	43	$14.85	$638.55	26,540
2/29/2024	Sell	1,845	$17.55	$32,379.75	26,994
2/27/2024	Sell	169	$19.80	$3,346.20	16,293
2/6/2024	Sell	280	$23.85	$6,678.00	16,463
9/1/2023	Sell	460	$19.95	$9,177.00	15,854
3/1/2023	Sell	747	$45.45	$33,951.15	16,357
6/3/2022	Sell	40	$90.60	$3,624.00	9,233
2/7/2022	Sell	263	$147.90	$38,897.70

Michael Mason Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $3.74

$3.73

$4.30

50 Day Range

MA: $8.05

$3.74

$10.50

2 Week Range

Now: $3.74

$3.73

$24.75

Volume

302,273 shs

Average Volume

78,935 shs

Market Capitalization

$31.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11